Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19193137 | 0.81 | UCHL1 (0.45) | UCHL1ALDH1A1MAPTLMNAKDM1A | |
| SCHEMBL31235963 | 0.81 | MAPK1 (0.44) | UCHL1ALDH1A1MAPTLMNAKDM1A | |
| SCHEMBL23063791 | 0.80 | NOTUM (0.64) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL31014046 | 0.80 | UCHL1 (0.52) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL1284259 | 0.80 | UCHL1 (0.67) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL29535019 | 0.80 | UCHL1 (0.67) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL3902861 | 0.80 | UCHL1 (0.52) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL28299110 | 0.80 | ALOX5 (0.46) | ALDH1A1NPC1RAB9A | |
| SCHEMBL19193156 | 0.80 | ALDH1A1 (0.43) | UCHL1ALDH1A1MAPTLMNANOTUM | |
| SCHEMBL868725 | 0.79 | NOTUM (0.65) | UCHL1NOTUMKDM1AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217997-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | ORMCO CORPORATION | 2017-08-03 | — | — | US | disclosed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
| WO-2012028106-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217997-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | SP1, GPER1, ESR1 | UCHL1 2667/4885ALDH1A1 869/4885MAPT 3354/4885 |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | UCHL1 1667/4885ALDH1A1 4512/4885MAPT 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.